Upexi, Inc. Form 8-K Summary
Business Context and Reporting Period
Upexi, Inc. filed a Form 8-K reporting the entry into and closing of a Membership Interest Purchase Agreement on October 26, 2022. Upexi sold 100% of the membership interests in Infusionz LLC to Bloomios, Inc. and its wholly owned subsidiary, Infused Confections LLC. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol UPXI.
Transaction Consideration and Key Financial Items
- Base transaction consideration: $23.5 million, subject to adjustment.
- Cash at closing: $5.5 million.
- Convertible secured subordinated promissory note: $5.0 million principal amount issued by Bloomios.
- Bloomios Series D Convertible Preferred Stock: 85,000 shares with an aggregate stated value of $8.5 million.
- Senior secured convertible debenture: $4.5 million subscription amount, with an original principal amount of $5.294 million after original issue discount.
- Warrant: Rights to purchase up to 2,853,910 shares of Bloomios common stock.
- Working capital adjustment: A two-way post-closing adjustment applies based on target working capital of $1.275 million.
The filing does not provide revenue, profit, cash flow, margins, total debt, liquidity balances, or other operating financial metrics for Upexi or Infusionz.
Material Changes Versus the Prior Comparable Period
The transaction represents a material disposition of Infusionz and removes Infusionz from Upexi’s wholly owned operations. The filing does not provide comparative operating results or quantify the transaction’s effect on consolidated revenue, earnings, cash flow, assets, liabilities, or liquidity.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or forward-looking operating outlook is provided.
- Upexi will receive significant non-cash consideration, including Bloomios preferred stock, convertible debt instruments, and a common stock warrant, creating exposure to the value, liquidity, dilution, and creditworthiness of Bloomios.
- The final consideration remains subject to the post-closing working capital adjustment.
- The filing cautions that the representations and warranties in the purchase agreement were negotiated for contractual risk allocation and may not represent factual or financial information applicable to investors.
- The transaction closed on October 26, 2022. A press release announcing the transaction was issued October 27, 2022.
Important Facts for Investors to Verify
- Whether the $5.5 million closing cash was received in full and the amount of any subsequent working capital adjustment.
- The terms, maturity, interest rate, conversion provisions, security, and collectability of the Bloomios promissory note and debenture.
- The market value, conversion terms, transferability, and dilution implications of the Bloomios preferred stock and warrant.
- Upexi’s accounting treatment, including any gain or loss on disposal and the impact on future consolidated results.
- Infusionz’s historical and expected contribution to Upexi’s revenue, earnings, cash flow, and liquidity.
- Bloomios’s ability to satisfy its obligations and the potential volatility or illiquidity of the securities received.